

Supplemental Table: Characteristics of SSPs (SSPs) by On-site HIV/HCV Testing Availability in the United States (N=127)

Program Characteristics	Any HIV and/or HCV onsite testing	No onsite HIV or HCV testing	p-value*
	Mean (Median)	Mean (Median)	
Number of syringes distributed (N=114)	341,533 (152,823)	260,688 (90,000)	0.69
Total SEP budget* (N=102)	\$184,733 (83,038)	\$30,882 (11,112)	<0.01
	n (%)	n (%)	
Location			0.37
Rural	22(19)	5 (36)	
Suburban	12 (11)	1 (7)	
Urban	79 (70)	8 (57)	
Region			0.03
Northeast	35 (31)	1 (7)	
Midwest	28 (25)	1 (7)	
South	13 (12)	3 (21)	
West	35 (31)	8 (57)	
Puerto Rico	2 (2)	1 (7)	
SEP program size (syringes dispensed)			0.32
Small (1-9,999)	6 (5)	2 (14)	
Medium (10,000-55,000)	19 (17)	4 (29)	
Large (55,001-499,999)	63 (56)	5 (36)	
Very Large (greater or equal to 500,000)	13 (12)	2 (14)	
None/unknown/missing	12 (11)	1 (7)	
Budget size			<0.01
<\$25,000	14 (12)	7 (50)	
\$25,000-\$100,000	32 (28)	4 (29)	
>\$100,000	44 (39)	1 (7)	
None/unknown/missing	23 (20)	2 (14)	
Receives Public Funding	76 (67)	5 (36)	0.04
Medical Billing			0.07
Currently uses medical billing	12 (11)	1 (7)	
Capacity for billing, but not currently using	27 (24)	0 (0)	
No capacity for medical billing	74 (65)	13 (93)	
Part of a larger organization	92 (81)	6 (43)	<0.01
Type of organization			0.18
Operated by city, county, or state health department	20 (18)	4 (29)	
Operated by another type of org	19 (17)	2 (14)	
Stand-alone non-profit org (tax exempt)	59 (53)	4 (29)	
Stand-alone other org	14 (13)	4 (29)	
Partnerships with other programs (not mutually exclusive)			
Joined a coalition or association with other SEPs (other than NASEN)	49 (43)	4 (29)	0.29
Partnered with a hospital to provide clinical services at your program	24 (21)	0 (0)	0.07
Partnered with a health care org to co-locate clinical and HR services	49 (43)	3 (21)	0.12
Partnered with a health care org to co-locate pharmacy services	21 (19)	1 (7)	0.46
Formed a partnership or joint venture with other SEPs	31 (27)	3 (21)	0.76
Merged with another SEP	6 (5)	0 (0)	0.99
Begun plans to merge with another SEP	7 (6)	0 (0)	0.99
Any Mobile Exchange	70 (62)	10 (71)	0.49
Detox offered on-site	3 (3)	0 (0)	0.99
Buprenorphine and/or methadone on-site	13 (12)	1 (7)	0.99

*Significant t-test or chi-square test at <0.05